Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients
| العنوان: | Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients |
|---|---|
| المؤلفون: | Suzanne Robertazzi, Andrea D. Branch, Helen S. Te, Coleman Smith, Michelle Lee Sang, Colleen Rodigas, Thomas D. Schiano, Janet Gripshover, Amber Tierney, Neal Patel, Mohamed Hassan, Darryn Potosky, Rohit Satoskar, Ryan M. Kwok, Joshua J Wiegel, Joseph Ahn |
| المصدر: | Liver Transplantation. 22:1536-1543 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Graft Rejection, Male, Sofosbuvir, medicine.medical_treatment, Hepacivirus, 030230 surgery, Liver transplantation, medicine.disease_cause, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Recurrence, Immunosuppression, Hepatitis C, Middle Aged, Drug Combinations, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Uridine Monophosphate, medicine.drug, Ledipasvir, medicine.medical_specialty, Hepatitis C virus, Calcineurin Inhibitors, Antiviral Agents, 03 medical and health sciences, Internal medicine, Pragmatic Clinical Trials as Topic, Ribavirin, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Immunosuppression Therapy, Fluorenes, Transplantation, Hepatology, business.industry, Hepatitis C, Chronic, medicine.disease, Liver Transplantation, Surgery, Calcineurin, chemistry, Benzimidazoles, business |
| الوصف: | Hepatitis C virus (HCV) recurrence after liver transplant (LT) is associated with worse outcomes. Ledipasvir and sofosbuvir (LDV/SOF) has been approved for HCV treatment after LT, but there is limited data on the effectiveness and safety of LDV/SOF in the “real world” setting. This multi-center study is the largest report to date, on the effectiveness and safety of LDV/SOF in the post-LT setting. Two hundred and four patients (72% male, 68% Caucasian, 66% genotype 1a, 21% METAVIR F3-F4, 49% treatment-experienced) were treated with LDV/SOF. The mean duration from LT to treatment initiation was 4.8 years. The overall sustained virologic response rate 12 weeks after completion of therapy (SVR12) was 96%. Patients treated with 8 or 12 weeks of LDV/SOF without RBV experienced an SVR12 rate of 100% and 96%, respectively. Calcineurin inhibitors were used in 89% of patients and 32% of patients underwent adjustment in immunosuppression during treatment. One episode of mild rejection, responsive to an increase in immunosuppression dosage, was observed. There was no graft loss attributed to HCV treatment. Four deaths occurred unrelated to HCV treatment, and no significant serious adverse events were documented. Conclusion: Sofosbuvir and ledipasvir with or without RBV for 8, 12, or 24 weeks in post LT patients was effective and safe with a high SVR12 rate across a spectrum of genotypes and stages of fibrosis. This article is protected by copyright. All rights reserved. |
| تدمد: | 1527-6473 1527-6465 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffcf1bd8fdc02995a1d45def92d212aTest https://doi.org/10.1002/lt.24614Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fffcf1bd8fdc02995a1d45def92d212a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15276473 15276465 |
|---|